Meeting
2013 Gastrointestinal Cancers Symposium
Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.
Authors
Ishwaria Subbiah
Division of Cancer Medicine, University of Texas M
Ishwaria Subbiah , Filip Janku , Apostolia Tsimberidou , Aung Naing , Ahmed Kaseb , David Hong , Vivek Subbiah , Kenneth Hess , Owais Akmal , Gerald Falchook , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr281)
DOI
10.1200/jco.2013.31.4_suppl.281
Abstract #
281
Poster Bd #
C29
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2023 ASCO Annual Meeting
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
First Author: Ming Liu
Poster
2022 ASCO Annual Meeting
ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).
First Author: Wen Wee Ma
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
First Author: Choong-kun Lee